688347-51-5

688347-51-5 structure

Name: SPL 334
Chemical Name: SPL-334
CAS Number: 688347-51-5
Molecular Formula: C₂₂H₁₅N₃O₃S₂
Molecular Weight: 433.503
Catalog: Signaling Pathways Metabolic Enzyme/Protease GSNOR
Create Date: 2021-01-07 20:56:42
Modify Date: 2024-01-12 17:59:11
SPL-334 is a potent and selective S-Nitrosoglutathione reductase (GSNOR) inhibitor. SPL-334 causes a significant reduction in the production of Th2 cytokines IL-5 and IL-13 and the levels of the chemokine CCL11 (eotaxin-1) in the airways. SPL-334 can be used in research of allergic airway inflammation[1].

Name	SPL-334
Synonyms	4-{[2-[(2-cyanobenzyl)thio]-4-oxothieno[3,2-d]pyrimidin-3(4H)-yl]methyl}benzoic acid Benzoic acid, 4-[[2-[[(2-cyanophenyl)methyl]thio]-4-oxothieno[3,2-d]pyrimidin-3(4H)-yl]methyl]- 4-({2-[(2-Cyanobenzyl)sulfanyl]-4-oxothieno[3,2-d]pyrimidin-3(4H)-yl}methyl)benzoic acid SPL-334 MFCD05032783

Description	SPL-334 is a potent and selective S-Nitrosoglutathione reductase (GSNOR) inhibitor. SPL-334 causes a significant reduction in the production of Th2 cytokines IL-5 and IL-13 and the levels of the chemokine CCL11 (eotaxin-1) in the airways. SPL-334 can be used in research of allergic airway inflammation[1].
Related Catalog	Signaling Pathways >> Metabolic Enzyme/Protease >> GSNOR Research Areas >> Inflammation/Immunology
In Vivo	SPL-334 (0.1-1 mg/kg; 鼻内给药; 每日一次, 持续 7 天; 带有 DO11.10 CD4+ Th2 异种移植物的 BALB/c 受体小鼠) 导致过敏性气道炎症减少[1] . Animal Model: BALB/c recipient mice with DO11.10 CD4+ Th2 xenograft[1] Dosage: 0.1 or 1 mg/kg Administration: Intranasal administration; daily, for 7 days Result: Caused a significant reduction in the influx of lymphocytes and eosinophils into the airways and the level of EPO in the BALF. Reduced the number of OVA-specific T cells and eosinophils during allergic airway inflammation. Reduced in peribronchial inflammation and mucus secretion during airway inflammation.
References	[1]. Ferrini ME, et, al. S-nitrosoglutathione reductase inhibition regulates allergen-induced lung inflammation and airway hyperreactivity. PLoS One. 2013 Jul 25;8(7):e70351.